Understanding companies’ fundamentals is vital for evaluating top stocks to buy. It helps one to make sharp investment decisions based on financial health, growth potential and competitive advantages. The below stocks remain undervalued and are industry leaders set for growth post-earnings season, making them ideal candidates to capitalize on the next major bull run.The first company excels in communication services, with strategic investments driving future growth. Meanwhile, the second company, in semicon ...

Growth stocks, known for rapid expansion and solid market positions, have outperformed for years. Despite not being market leaders yet, they possess the potential to dominate. For long-term investors seeking high upside potential, these growth stocks are compelling choices. Although riskier than big names, their strong fundamentals and competitive edge can drive significant gains. Despite numerous S&P 500 companies reporting losses, top performers tend to outperform this index and others. However, performan ...

Join the seven million loyal Allē Members in celebrating the second annual JUVÉDERM® Day on August 21, 2024Members receive an exclusive gift card offer and a chance to win $10,000*IRVINE, Calif., July 30, 2024 /PRNewswire/ -- Allergan Aesthetics, an AbbVie company (NYSE: ABBV), today announced the return of JUVÉDERM® Day on Wednesday, August 21. After a successful first year, JUVÉDERM® Day is back with limited time offers, savings, and exclusive deals through Allē, the Allergan Aesthetics loyalty rewards pr ...

Morsa Images/DigitalVision via Getty ImagesSince my last article was published on April 29, AbbVie's share price (NYSE:ABBV) has risen more than 16%, hitting new multi-year highs. This article will focus not only on the company's Q2 2024 financial results but also on other factors that make me believe it is becoming an increasingly attractive stock among Big Pharma despite the lack of significant progress in developing its oncology franchise. AbbVie's Q2 2024 financial results were beyond praise AbbVie' ...

High-yield dividend stocks are attractive investment options as they provide regular payouts regardless of market performance. Understanding dividend yield, which is a ratio showing annual dividend income per dollar invested, is crucial for comparing investments.The yield, expressed as a percentage of the current price, indicates the annual return on investment at the purchase price. Reinvesting dividends can significantly enhance returns due to compounding.Divide the annual dividend per share by the share ...

Investment Thesis - The stock of AbbVie (ABBV) has notably outperformed the broader U.S. market since mid-April, reinforcing the initial bullish thesis [1] - The company delivered robust Q2 earnings with revenue growth across all business lines and expanding operating leverage, indicating efficient growth management [1] - The valuation remains attractive, and the "Strong Buy" rating is reiterated [1] Financial Analysis and Q2 Earnings Review - ABBV reported a solid Q2 revenue beat, with revenue growing by 4.3% YoY and operating margin expanding from 34.4% to 35.1% [2][3] - Despite EPS figures below consensus estimates, the stock rallied by more than 5% post-earnings due to an upgraded full-year EPS guidance [2] - Humira's revenue decline was expected due to patent expiration, but younger products like Skyrizi and Rinvoq showed immense growth momentum [3] Revenue Breakdown by Product - Humira's revenue declined significantly, with Q2 2024 revenue at $2,814 million, down 29.9% YoY [4] - Skyrizi and Rinvoq demonstrated strong growth, with Skyrizi revenue at $2,727 million (up 44.8% YoY) and Rinvoq at $1,430 million (up 55.8% YoY) in Q2 2024 [4] Business Segment Growth - ABBV achieved revenue growth across all business lines: Immunology, Oncology, Neuroscience, and Aesthetics, indicating a robust and resilient business mix [5] - The company's R&D efficiency is highlighted, with R&D expenses translating into successful product launches [5] Immunology Market Position - ABBV holds a 25% market share in the immunology drugs market, which was valued at $98.5 billion in 2023 [7] - Skyrizi and Rinvoq are expected to drive significant growth, with U.S. patents expiring in 2033, ensuring no generic competition until then [7] Oncology and Aesthetics Market Outlook - The oncology drugs market is projected to grow at an 11.3% CAGR by 2032, and ABBV's success across business lines suggests potential for growth in this niche [8] - The aesthetics market, driven by social media influence, is expected to show double-digit CAGR by 2033, with ABBV's Botox product maintaining a strong position [9] Valuation Update - ABBV's valuation ratios appear high, but historical comparisons are skewed due to recent revenue and profit spikes post-Allergan acquisition [10] - The dividend discount model (DDM) suggests a fair value of $249, representing a 35% upside from the current share price [13] Risks and Competition - ABBV faces competition in the immunology market, with alternative therapies emerging [14] - The company's reliance on new products like Skyrizi and Rinvoq to replace Humira's revenue is a key risk, as future success is not guaranteed [14] Bottom Line - ABBV remains a "Strong Buy" due to strong Q2 earnings, robust fundamentals, and attractive valuation, despite recent market outperformance [16]

--INVOKE-2 is the first global Phase 2 trial evaluating the safety and efficacy of a TREM2 agonist, AL002, in slowing disease progression in individuals with early Alzheimer's disease (AD)-- --Baseline characteristics data for the INVOKE-2 study confirm a representative study population that enables testing of the effects of a novel TREM2 agonist in early AD-- SOUTH SAN FRANCISCO, Calif., July 28, 2024 (GLOBE NEWSWIRE) -- Alector, Inc. (NASDAQ:ALEC), a clinical-stage biotechnology company pioneering immuno- ...

The marketing authorization for SKYRIZI® (risankizumab) marks its fourth approved indication in the European Union The approval is supported by data from two pivotal Phase 3 trials: The INSPIRE induction trial1 and COMMAND maintenance trial2 In both trials, SKYRIZI achieved the primary endpoint of clinical remission (per Adapted Mayo Score*) and key secondary endpoints, including mucosal healing** and histologic endoscopic mucosal healing†,1,2 NORTH CHICAGO, Ill., July 26, 2024 /PRNewswire/ -- AbbVie (NYS ...

The market was impressed with a notable increase in full-year guidance.AbbVie (ABBV 3.38%) stock was the cure for what ails a portfolio on Thursday. The sturdy pharmaceutical company was a favorite of investors, who were trading its shares up by nearly 4% in price in late-session action. This occurred in the wake of the company's latest quarterly earnings release published that morning.Sales drops and sales leapsFor its second quarter, AbbVie earned just under $14.5 billion in revenue. That figure was more ...

Key TakeawaysAbbVie reported strong sales of its other medicines as demand for Humira fell because of competition from biosimilar drugs.Revenue from rheumatoid arthritis medicines Rinvoq and Skyrizi soared.The news sent AbbVie shares to an all-time high in intraday trading Thursday. AbbVie (ABBV) shares traded at an all-time high Thursday as the biopharmaceutical firm posted better-than-expected revenue and boosted its guidance as demand for its other drugs offset a decline in Humira sales. The company repo ...